The series C1 round pushed the Sanofi and Alexandria Real Estate Equities-backed oral therapeutics developer’s total funding to about $200m.

Dice Molecules, a US-based biopharmaceutical developer backed by pharmaceutical firm Sanofi and life sciences real estate investment trust Alexandria Real Estate Equities, closed a $60m series C1 round yesterday.

RA Capital Management and Sands Capital co-led the round, which included Osage University Partners (OUP), Janus Henderson Investors, Deep Track Capital, Logos Capital, Northpond Ventures, Eventide Asset Management, Driehaus Capital Management, Soleus Capital, New Leaf Venture Partners and Asymmetry Capital.

Founded in 2014, Dice is working on a drug discovery platform…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn